Tuberculosis (TB) continues to be a significant infectious disease in many developing countries, and among these countries, India has the highest burden of TB. Addressing the challenges of Drug-Induced Liver Injury (DILI) in antitubercular treatment is crucial for optimizing TB management and improving patient outcomes. In this video, let's take a closer look at the challenges posed by DILI in antitubercular treatment.
Please login to comment on this article